Nobody but us can make mesenchymal stem cells with as much reliability or efficacy, and do it in volume. That's our business model. Until people promoting competition can point to some proof that this is not the case, I think it's fair that we make this point here.
Ann: Ethics Approval & Expedited Pathway for Phase 3 OA Trial, page-169
-
- There are more pages in this discussion • 327 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.0¢ |
Change
0.010(5.56%) |
Mkt cap ! $35.23M | |||
| Open | High | Low | Value | Volume |
| 18.0¢ | 19.5¢ | 18.0¢ | $9.062K | 48.88K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 125117 | 18.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.0¢ | 25074 | 2 |
View Market Depth
| Last trade - 14.37pm 12/09/2024 (20 minute delay) ? |
| CYP (ASX) Chart |